A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


January 24, 2013

U.K. Throws Weight Behind Treatment as Prevention Model

The U.K. Department of Health has published a position paper by England’s Expert Advisory Group on AIDS (EAGA) and the British HIV Association (BHIVA) on the use of antiretroviral therapy to prevent HIV transmission, calling vaginal transmission risk “extremely low” when the HIV-positive partner maintains an undetectable viral load and is free of sexually transmitted infections (STIs). The paper also asserts that successful ARV therapy is “as effective as consistent condom use in limiting viral transmission.”

Drawing upon studies such as the famed HPTN 052 trial that showed a 96 percent reduction in transmission risk when the HIV-positive partner of a serodiscordant heterosexual couple is taking effective HIV meds, EAGA and BHIVA recommend health care professionals discuss with their HIV-positive patients how proper ARV use may help prevent transmission. Their paper also encourages providers to discuss the potential for beginning therapy with those people living with the virus who wish to reduce their likelihood of transmitting to others.

The paper delineates three caveats that must be in place to ensure the best possible protection against transmission in heterosexual couples:

  • Neither partner must be infected with an STI (which can both make people more susceptible to becoming infected with HIV and which can raise viral loads in people living with the virus, making them more infectious).
  • The HIV-positive partner must have sustained an undetectable viral load for more than six months and have had an undetectable viral load on his or her last test.
  • Viral load tests should be conducted every three to four months.
While the authors of the paper acknowledge that there has been insufficient research to indicate whether ARVs protect similarly with sexual practices outside of vaginal sex, such as anal sex, they assert their expert opinion that the “extremely low risk” is likely similar when the above conditions are met.

“It must be noted that no single prevention method can completely prevent HIV transmission,” the paper states. “Antiretroviral therapy reduces the risk of transmission only of HIV. Irrespective of antiretroviral therapy, condoms remain the most effective way to prevent the spread of other sexually transmitted infections.”

The British groups’ pronouncement comes five years almost to the day after the Swiss Federal Commission for HIV/AIDS stated that heterosexual people with HIV cannot infect others if they are on successful ARVs, maintain an undetectable viral load and have no STIs. Many HIV advocates consider the BHIVA to be an especially cautious and conservative group, making its own bold statement about the matter all the more notable.

To read to position paper, click here.

Search: Expert Advisory Group on AIDS, EAGA, British HIV Association, BHIVA, transmission, treatment as prevention, antiretroviral therapy, ARV, sexually transmitted infections, undetectable viral load, serodiscordant couple, HPTN 052, Swiss Federal Commission for HIV/AIDS, U.K. Department of Health.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

comments 1 - 1 (of 1 total)    

Jeton Ademaj, Harlem, NYC, 2013-02-07 12:19:29
This is enormously significant...the only bigger prize in validating TAsP will be when the US NIH and CDC issue a similar statement. hopefully at some point it will be practical to *prove* to someone that u r "consistently undetectable" without having to give them a HIPPA release a/o take them to ur doctor's office. frankly, getting to play RAW without fear of HIV or criminality proves a FANTASTIC incentive for Treatment Adherence. yup, read that again...n again. Treatment As Prevention WORKS!

comments 1 - 1 (of 1 total)    

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.